The Disparate State Impacts and Enormous Cost of a Gas Tax Holiday
Legislative interest in suspending the federal gas tax in response to high fuel prices gained support recently when President Trump told a reporter, “I think it’s a great idea.”
Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
Senator Cory Booker (D-NJ) recently proposed a bold tax plan that includes drastically increasing the standard deduction from $16,100 to $37,500 for single filers ($32,200 to $75,000 for married couples filing jointly).
FDA Continues to Expedite Biosimilar Development
Following its move in October to eliminate comparative efficacy studies for biosimilars in development, last week the FDA made further strides to streamline the biosimilar approval process in the United States.
Diminishing Returns from the Government’s Drug Negotiation Program
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the next 15 drugs that will be subject to government price negotiations.
Would Senate Passage of an ACA Tax Credit Extension Matter?
Last week, under a rarely used procedure known as a discharge motion, the House of Representatives passed a three-year extension of the enhanced Affordable Care Act (ACA) healthcare tax credit, which expired on December 31.
FDA Moves to Facilitate Biosimilar Development
Yesterday, the Food and Drug Administration (FDA) announced long-overdue reforms to the biosimilar approval process that will boost biosimilar development and competition in the United States.
- The Disparate State Impacts and Enormous Cost of a Gas Tax Holiday
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
